Free Trial
NYSE:TMO

Thermo Fisher Scientific (TMO) Stock Price, News & Analysis

$598.61
-2.31 (-0.38%)
(As of 10/4/2024 08:51 PM ET)

About Thermo Fisher Scientific Stock (NYSE:TMO)

Key Stats

Today's Range
$596.53
$603.99
50-Day Range
$587.37
$624.21
52-Week Range
$415.60
$627.88
Volume
871,500 shs
Average Volume
1.48 million shs
Market Capitalization
$228.67 billion
P/E Ratio
38.40
Dividend Yield
0.26%
Price Target
$653.72
Consensus Rating
Moderate Buy

Company Overview

Thermo Fisher Scientific Inc. is a prominent American supplier of scientific instrumentation, reagents, consumables, and software services. The company was formed in 2006 through the merger of Thermo Electron and Fisher Scientific, established players in the scientific and laboratory equipment industry. Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific operates in the life sciences, healthcare, and analytical technologies sectors.

The company's history dates back to 1956 when Thermo Electron was co-founded by George N. Hatsopoulos and Peter M Nomikos, focusing on analytical and laboratory products. Fisher Scientific, founded in 1902 by Chester G. Fisher, supplied laboratory equipment, chemicals, and services. The merger in 2006 created Thermo Fisher Scientific, combining their expertise and product portfolios to provide comprehensive solutions to scientific and healthcare communities.

Thermo Fisher Scientific's mission is to enable customers to make the world healthier, cleaner, and safer through its innovative products and services. They strive to advance research, enhance healthcare and support analytical applications globally. The company offers a wide range of products and services under the brand names of Thermo Scientific, Fisher Scientific, and others. Their offerings include advanced instruments, consumables, reagents, software, and services tailored for research, diagnostics, and industrial applications. Thermo Fisher Scientific's products are utilized by academic institutions, pharmaceutical companies, biotech firms, healthcare providers, and research organizations worldwide.

Thermo Fisher Scientific's management team is led by Mr. Marc N. Casper, who serves as Chairman, President, and Chief Executive Officer. Under his leadership, the company has grown remarkably and expanded its global footprint. 

Thermo Fisher Scientific has exhibited strong financial performance in recent years. The company's annual revenue and net income have been increasing yearly. The net profit margin stands at over 10%, demonstrating the company's ability to convert revenue into profit efficiently. The company maintains a healthy financial position with a debt-to-equity ratio indicating that it relies less on debt financing and holds a strong balance sheet confirming its financial stability and ability to meet short-term obligations.

Thermo Fisher Scientific's valuation metrics show positive signs. The market has expressed confidence in the company's future earnings potential, and that confidence is reflected in its valuation metrics. This indicates that investors are optimistic about the company's future growth prospects. Thermo Fisher Scientific's stock has demonstrated solid performance, which suggests investors' positive sentiment toward the company. However, various factors, including macroeconomic conditions, industry trends, and company-specific developments, can influence market performance.

Thermo Fisher Scientific operates in the measuring and controlling devices industry, specifically life sciences tools and services. The company is a dominant player in this industry, benefiting from its vast product portfolio and global reach. Its comprehensive offerings and strong customer relationships provide a competitive advantage over peers. With a diverse customer base and innovative solutions, the company is well-positioned to capitalize on the growing demand for advanced scientific and healthcare products. Thermo Fisher Scientific enjoys a competitive edge in the industry due to its extensive product range, technical expertise, and established market presence. The company's continuous investments in research and development enable it to introduce cutting-edge products that cater to evolving customer needs. Additionally, strategic acquisitions have expanded its capabilities, strengthening its competitive positioning.

The company has numerous growth opportunities in the life sciences, healthcare, and industrial sectors. The rising demand for innovative research tools, diagnostic solutions, and analytical instruments presents attractive prospects for Thermo Fisher Scientific. The company's strong global presence allows it to tap into emerging markets and cater to a diverse customer base. Thermo Fisher Scientific possesses several competitive advantages, including its vast product portfolio, research capabilities, and established reputation in the industry. Its ability to provide end-to-end solutions across multiple sectors sets it apart from competitors. Moreover, strategic partnerships and acquisitions have facilitated access to new technologies and expanded its customer base, bolstering its competitive position.

Despite its strengths, Thermo Fisher Scientific faces certain risks and challenges. Market competition from established players and emerging companies could impact market share and pricing power. Global economic conditions and regulatory changes may influence the company's operations and profitability. Moreover, unexpected events like supply chain disruptions or technology shifts could pose challenges. Thermo Fisher Scientific employs robust risk management strategies to mitigate potential risks. These include diversifying its product portfolio, investing in research and development, and maintaining financial stability. The company continuously monitors market dynamics to adapt to changing trends and demands. Additionally, strong governance and compliance practices ensure adherence to regulatory requirements.

Thermo Fisher Scientific Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
95th Percentile Overall Score

TMO MarketRank™: 

Thermo Fisher Scientific scored higher than 95% of companies evaluated by MarketBeat, and ranked 70th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Thermo Fisher Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 16 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Thermo Fisher Scientific has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Thermo Fisher Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Thermo Fisher Scientific are expected to grow by 10.22% in the coming year, from $21.72 to $23.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Thermo Fisher Scientific is 38.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Thermo Fisher Scientific is 38.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 124.08.

  • Price to Earnings Growth Ratio

    Thermo Fisher Scientific has a PEG Ratio of 3.88. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Thermo Fisher Scientific has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Thermo Fisher Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    1.05% of the float of Thermo Fisher Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Thermo Fisher Scientific has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Thermo Fisher Scientific has recently increased by 12.71%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Thermo Fisher Scientific has a dividend yield of 0.25%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Thermo Fisher Scientific does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Thermo Fisher Scientific is 10.01%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Thermo Fisher Scientific will have a dividend payout ratio of 6.52% next year. This indicates that Thermo Fisher Scientific will be able to sustain or increase its dividend.

  • Read more about Thermo Fisher Scientific's dividend.
  • Percentage of Shares Shorted

    1.05% of the float of Thermo Fisher Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Thermo Fisher Scientific has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Thermo Fisher Scientific has recently increased by 12.71%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Thermo Fisher Scientific has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 26 news articles for Thermo Fisher Scientific this week, compared to 13 articles on an average week.
  • Search Interest

    Only 16 people have searched for TMO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Thermo Fisher Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Thermo Fisher Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,094,292.00 in company stock.

  • Percentage Held by Insiders

    Only 0.34% of the stock of Thermo Fisher Scientific is held by insiders.

  • Percentage Held by Institutions

    89.23% of the stock of Thermo Fisher Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Thermo Fisher Scientific's insider trading history.

TMO Stock News Headlines

Thermo Fisher Scientific (TMO)
25-Yr Wall St Legend: Get Out of Cash before Nov 6
Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.
Thermo Fisher Scientific: Fantastic Company, Rich Valuation
See More Headlines

TMO Stock Analysis - Frequently Asked Questions

Thermo Fisher Scientific's stock was trading at $530.79 at the beginning of the year. Since then, TMO stock has increased by 12.8% and is now trading at $598.61.
View the best growth stocks for 2024 here
.

Thermo Fisher Scientific Inc. (NYSE:TMO) posted its quarterly earnings data on Wednesday, July, 24th. The medical research company reported $5.37 earnings per share for the quarter, beating analysts' consensus estimates of $5.13 by $0.24. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year.
Read the conference call transcript
.

Thermo Fisher Scientific's board approved a share buyback program on Tuesday, November 14th 2023, which permits the company to buy back $4,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 2.2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board believes its shares are undervalued.

Thermo Fisher Scientific subsidiaries include Henogen, Phinotex, Qiagen, Brammer Bio, HighChem, Gatan Inc, IntegenX, and others.

Thermo Fisher Scientific's top institutional investors include Handelsbanken Fonder AB (0.10%), Neville Rodie & Shaw Inc. (0.02%), Czech National Bank (0.02%) and AMF Tjanstepension AB (0.02%). Insiders that own company stock include Marc N Casper, Stephen Williamson, Gianluca Pettiti, Michel Lagarde, Jim P Manzi, Lisa P Britt, Michael A Boxer, Joseph R Holmes, Debora L Spar and Mark Stevenson.
View institutional ownership trends
.

Shares of TMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Thermo Fisher Scientific investors own include Johnson & Johnson (JNJ), Home Depot (HD), NVIDIA (NVDA), Cisco Systems (CSCO), Alibaba Group (BABA), Walt Disney (DIS).

Company Calendar

Ex-Dividend for 7/15 Dividend
6/14/2024
Dividend Payable
7/15/2024
Last Earnings
7/24/2024
Ex-Dividend for 10/15 Dividend
9/13/2024
Today
10/07/2024
Dividend Payable
10/15/2024
Next Earnings (Confirmed)
10/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Measuring & controlling devices, not elsewhere classified
Sub-Industry
Life Sciences Tools & Services
CUSIP
88355610
Employees
122,000
Year Founded
1956

Price Target and Rating

Average Stock Price Target
$653.72
High Stock Price Target
$767.00
Low Stock Price Target
$575.00
Potential Upside/Downside
+9.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
21 Analysts

Profitability

Net Income
$6.00 billion
Pretax Margin
16.20%

Debt

Sales & Book Value

Annual Sales
$42.86 billion
Cash Flow
$29.77 per share
Book Value
$120.93 per share

Miscellaneous

Free Float
380,418,000
Market Cap
$228.67 billion
Optionable
Optionable
Beta
0.77

Social Links


This page (NYSE:TMO) was last updated on 10/7/2024 by MarketBeat.com Staff
From Our Partners